Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.51 |
| ▸ | ANPEP | P15144 | 2/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | CPA3 | P15088 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052906 | 0.91 | ANPEP (0.54) | TBXAS1ANPEPERAP1ERAP2FOLH1 | |
| SCHEMBL6037797 | 0.86 | CPA3 (0.56) | FOLH1CPA3 | |
| SCHEMBL5053018 | 0.84 | TBXAS1 (0.55) | TBXAS1ANPEPERAP1ERAP2 | |
| SCHEMBL5053137 | 0.81 | GRM3 (0.54) | ANPEPERAP1ERAP2FOLH1 | |
| SCHEMBL6422716 | 0.80 | ANPEP (0.57) | ANPEPERAP1ERAP2FOLH1CPA3 | |
| SCHEMBL6037784 | 0.79 | TSHR (0.60) | FOLH1CPA3 | |
| SCHEMBL5059776 | 0.78 | TBXAS1 (0.50) | TBXAS1ANPEPERAP1ERAP2 | |
| SCHEMBL7613096 | 0.78 | TBXAS1 (0.50) | TBXAS1ANPEPERAP1ERAP2 | |
| SCHEMBL6037839 | 0.77 | CPA3 (0.58) | FOLH1CPA3 | |
| SCHEMBL7613970 | 0.76 | FOLH1 (0.53) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |